Premenstrual dysphoric disorder (PMDD) !
A severe, cyclical mood disorder in the week or two before menstruation that clearly improves within a few days after bleeding starts.
Updated 2026-11-01
Structures involved
Tap one to see what it is and open it in 3D.
Why it happens
What it is
A depressive disorder tied to the menstrual cycle. Marked mood symptoms (irritability, mood swings, depressed mood or anxiety) plus physical and behavioural symptoms appear in the luteal phase, improve within a few days of the onset of menses and are minimal or absent in the week after menses. Unlike ordinary premenstrual syndrome (PMS), the symptoms cause clear distress or impair work, study or relationships.
Who gets it
Affects a small minority of people who menstruate (roughly 3 to 8% in most studies), whereas milder premenstrual symptoms are very common. It can start any time after menarche and often worsens in the late reproductive years, ending at menopause. In Colombia and Latin America it is under-recognised; many patients first consult gynaecology or primary care for 'PMS' rather than mental health services.
Causes
- Abnormal brain sensitivity to the normal cyclical rise and fall of oestrogen and progesterone (hormone levels themselves are usually normal)
- Altered response to progesterone metabolites such as allopregnanolone, which act on GABA-A receptors
- Reduced serotonergic function in the luteal phase
- Genetic susceptibility, suggested by family and twin studies
Risk factors
- Personal or family history of depression, anxiety or postpartum depression
- History of trauma or high psychosocial stress
- Previous PMDD-like symptoms with hormonal contraceptives
- Smoking and higher body mass index in some studies
- Late reproductive age (symptoms often intensify before menopause)
Pathophysiology
Symptoms are triggered by ovulation and the luteal-phase hormone changes rather than by abnormal hormone levels. In susceptible individuals, the hypothalamic and limbic circuits (amygdala, prefrontal cortex) respond abnormally to fluctuating oestrogen, progesterone and allopregnanolone, with reduced serotonin signalling. Suppressing ovulation abolishes the symptoms, which is why ovarian suppression is effective in refractory cases.
Classification
- PMS: mild to moderate premenstrual symptoms without major impairment
- PMDD: at least 5 cyclical symptoms, at least 1 of them affective, with clear impairment
- Premenstrual exacerbation: worsening of an underlying disorder (such as major depression) before menses, with symptoms persisting through the rest of the cycle
Symptoms and signs
- Marked mood swings, sudden sadness or tearfulness, sensitivity to rejection
- Marked irritability or anger and increased interpersonal conflict
- Depressed mood, hopelessness or self-critical thoughts
- Anxiety, tension or feeling on edge
- Reduced interest, poor concentration, fatigue, appetite changes or food cravings, sleep changes, feeling overwhelmed
- Physical symptoms: breast tenderness or swelling, bloating, weight gain, joint or muscle pain
Diagnosis
- Clinical
- Clinical diagnosis confirmed by prospective daily symptom ratings over at least 2 symptomatic menstrual cycles, showing symptoms in the final week before menses, improvement within a few days after menses begin, and a symptom-free interval after menses. At least 5 symptoms, including at least 1 core mood symptom, with significant distress or impairment.
- Tests
- No laboratory test confirms PMDD. Hormone levels are not useful. Thyroid function tests and a complete blood count may be ordered to exclude hypothyroidism or anaemia; a pregnancy test when relevant.
- Imaging
- Not needed. Pelvic ultrasound only if there is a separate gynaecological concern such as pelvic pain or abnormal bleeding.
Differential diagnosis
- Premenstrual syndrome (milder, without major impairment)
- Premenstrual exacerbation of major depressive or anxiety disorder
- Bipolar disorder
- Hypothyroidism
- Perimenopause
- Dysmenorrhoea and endometriosis (pain-predominant)
Goal of treatment
Reduce cyclical mood and physical symptoms, restore function and ensure safety, starting with the least invasive effective option.
Treatment
- Lifestyle
- Lifestyle measures: regular aerobic exercise, sleep regularity, stress reduction and limiting alcohol and caffeine; a symptom diary also helps the patient anticipate difficult days.
- Conservative
- Cognitive behavioural therapy, alone or added to medication, to manage mood symptoms and interpersonal conflict.
- Medical
- First-line drug class: selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine or sertraline, given continuously or only in the luteal phase; they act faster in PMDD than in depression.
- Medical
- Ovulation suppression with a combined oral contraceptive (for example one containing drospirenone), especially when contraception is also wanted.
- Medical
- Refractory cases: specialist use of gonadotropin-releasing hormone (GnRH) agonists with add-back hormone therapy; bilateral oophorectomy is a last resort reserved for severe, proven cases.
- Follow-up
- Monitoring of symptom diaries, side effects and suicidal thoughts at each review.
Complications
- Impaired work, study and relationships every cycle
- Suicidal thoughts and attempts concentrated in the premenstrual phase
- Coexisting major depression or anxiety disorders
- Higher risk of perinatal and perimenopausal depression
Prognosis
PMDD tends to recur every cycle until menopause, but most patients improve substantially with SSRIs or ovulation suppression. Symptoms stop during pregnancy and after menopause, and often recur when treatment is stopped.
Test yourself
Think of the answer, then tap the question to see it.
What timing pattern defines PMDD?
Symptoms in the final week before menses, improvement within a few days after menses begin, and minimal or no symptoms in the week after menses.
How is the diagnosis confirmed?
Prospective daily symptom ratings over at least 2 symptomatic cycles; there is no diagnostic blood test.
What is the first-line drug class for PMDD?
Selective serotonin reuptake inhibitors (SSRIs), given continuously or only in the luteal phase.
A patient's low mood persists all month but worsens before menses. What is the likely diagnosis?
Premenstrual exacerbation of an underlying depressive disorder, not PMDD.
Why do GnRH agonists help refractory PMDD?
They suppress ovulation and the cyclical hormone fluctuations that trigger symptoms.
Related conditions
- Major depressive disorder
- Persistent depressive disorder (dysthymia)
- Perinatal depression and postpartum psychosis
- Bipolar disorder
- Generalized anxiety disorder
- Dysmenorrhoea
- Endometriosis
- Hypothyroidism
- Suicidal behaviour and suicide risk
Educational information, not medical advice. For any symptom, see a health professional.
Sources: Premenstrual dysphoric disorder (MedlinePlus (U.S. National Library of Medicine), 2025).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
